Akari Therapeutics (AKTX) Long-Term Debt Issuances (2014)

Akari Therapeutics' (AKTX) quarterly Long-Term Debt Issuances came in at $432353.0 in Q4 2014.

Akari Therapeutics (AKTX) Long-Term Debt Issuances (2014) Analysis & Trends

Akari Therapeutics has disclosed Long-Term Debt Issuances across 1 years of filings, most recently posting $432353.0 for Q4 2014.

Long-Term Debt Issuances for Q4 2014 came in at $432353.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $432353.0 (changed N/A YoY), and the FY2025 annual result was $2.1 million, up 109.9% from the prior year.
Long-Term Debt Issuances came in at $432353.0 for Q4 2014 at Akari Therapeutics.
In the past five years, Long-Term Debt Issuances ranged from a high of $432353.0 in Q4 2014 to a low of $432353.0 in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	2.73 Mn
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Regeneron Pharmaceuticals	63.43 Bn	54.67 Bn	3.31 Bn	-

Download Data

Date	Value
Dec 31, 2014	432,353.00
Dec 31, 2014	432,353.00